 | Stephen David SilbersteinDepartment of Neurology, Jefferson Headache Center, Thomas Jefferson University, 900 Walnut Street, Suite 200, 19107, Philadelphia, PA, USA | Jefferson Headache Center, ... |
KOL Resume for Stephen David Silberstein (chronic rheumatic pericarditis, acute, fever, rheumatic, disease, acute rheumatic fever)
| Year | |
|---|---|
| 2022 | Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, 900 Walnut Street, Suite 200, 19107, Philadelphia, PA, USA Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, United States |
| 2021 | Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA USA |
| 2020 | Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. |
| 2019 | Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA |
| 2018 | Department of Neurology, Thomas Jefferson University, Philadelphia, PA. Thomas Jefferson University, Philadelphia, PA |
| 2017 | Department of Neurology, Jefferson Headache Center, Philadelphia, PA, USA, View further author information From the Jefferson Headache Center, Thomas Jefferson University, Philadelphia (S.D.S.), and Teva Pharmaceuticals, Frazer (M.E.B., P.P.Y., T.B., M.G.-W., R.Y., Y.M., E.A.) - both in Pennsylvania; Mayo Clinic Arizona, Phoenix (D.W.D.); and National Institute for Health Research-Wellcome Trust King's Clinical Research Facility, King's College London, London (P.J.G.). Jefferson Headache Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania |
| 2016 | a Jefferson Headache Center , Thomas Jefferson University , Philadelphia , PA , USA. |
| 2015 | Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA. Mayo Clinic Arizona Department of Neurology Scottsdale AZ USA |
| 2014 | Thomas Jefferson University, Jefferson Medical College, Jefferson Headache Center, 900 Walnut Street, Suite 200, Philadelphia, PA 19107, USA +215 955 2243; +1 215 955 2060; Jefferson Headache Center, PA, USA |
| 2013 | Jefferson Headache Center, 111 South 11th Street, Suite 8130, Philadelphia, PA 19107, USA |
| 2012 | From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA; Comprehensive Headache Center (F.F.), Baylor University Headache Medicine Center, Dallas, TX; Mayo Clinic (D.D.), Scottsdale, AZ; New York University School of Medicine (C.A.), Albany; and Elmendorf Air Force Base (E.A.), AK. Thomas Jefferson University, USA |
| 2011 | From the Neurological Institute, Cleveland Clinic Center for Headache and Pain, Cleveland, OH, USA (S.J. Tepper); MAP Pharmaceuticals, Mountain View, CA, USA (S.H. Kori, S.W. Borland, M.H. Wang, and B. Hu); Houston Headache Clinic, Houston, TX, USA (N.T. Mathew); Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA (S.D. Silberstein) Thomas Jefferson University, USA. |
Prominent publications by Stephen David Silberstein
OBJECTIVE: To assess the effectiveness of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain.
DESIGN: Three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies.
SETTING: Private practice, referral centers, and general community.
PATIENTS: Migraineurs with moderate or severe headache pain who met International Headache Society diagnostic criteria for migraine with aura or without aura. The most ...
| Known for Migraine Headache | Aspirin Caffeine | Patients Pain | Nonprescription Combination | Nausea Photophobia |
OBJECTIVE: To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine.
BACKGROUND: Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. Few preventive treatments have been investigated and none is specifically indicated for chronic migraine.
METHODS: The 2 multicenter, pivotal trials in the PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy clinical program each ...
| Known for Chronic Migraine | Headache Frequency | Onabotulinumtoxina Placebo | Baseline Week | Preempt Clinical |
OBJECTIVE: The objective of this study was to compare the efficacy, tolerability, and safety of AVP-825, an investigational bi-directional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder, vs 100 mg oral sumatriptan for acute treatment of migraine in a double-dummy, randomized comparative efficacy clinical trial allowing treatment across multiple migraine attacks.
BACKGROUND: In phases 2 and 3, randomized, placebo-controlled trials, AVP-825 ...
| Known for Oral Sumatriptan | Acute Treatment | Compass Study | Intranasal Administration | Pain Relief |
BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is important in migraine pathophysiology. We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine.
METHODS: This was a phase 2, randomised, double-blind, placebo-controlled, multicentre study of erenumab for adults aged 18-65 years with chronic migraine, enrolled from 69 headache and clinical research centres in North America and Europe. ...
| Known for Chronic Migraine | Safety Erenumab | Adverse Events Placebo | Preventive Treatment | 4 Weeks |
BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine.
METHODS: In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of any duration or severity on ≥15 days per month and migraine on ≥8 days per month) in a 1:1:1 ratio to receive ...
| Known for Chronic Migraine | Fremanezumab Placebo | Preventive Treatment | Headache Month | Monoclonal Antibodies |
OBJECTIVE: To assess the efficacy and safety of botulinum toxin type A (BoNT-A; BOTOX, Allergan, Inc., Irvine, CA) for the prophylaxis of headaches in patients with chronic daily headache (CDH) without the confounding factor of concurrent prophylactic medications.
BACKGROUND: Several open-label studies and an 11-month, randomized, double-blind, placebo-controlled study suggest that BoNT-A may be an effective therapy for the prophylaxis of headaches in patients with CDH.
DESIGN AND ...
| Known for Chronic Daily Headache | Baseline Bonta | Prophylactic Medications | Botulinum Toxin Type | Patients Cdh |
BACKGROUND: Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.
METHODS: In this multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel-group phase 2b study, we enrolled men and women (aged 18-65 years) from 62 sites in the USA who had chronic ...
| Known for Preventive Treatment | Chronic Migraine | Patients Placebo | Safety Tolerability | 675 225 |
BACKGROUND: Calcitonin gene-related peptide (CGRP) is crucial in the pathophysiology of migraine. We assessed the safety, tolerability, and efficacy of ALD403, a genetically engineered humanised anti-CGRP antibody, for migraine prevention.
METHODS: In this randomised, double-blind, placebo-controlled, exploratory, proof-of-concept phase 2 trial, patients aged 18-55 years with five to 14 migraine days per 28-day period were randomly assigned (1:1) via an interactive web response system to ...
| Known for Migraine Patients | 2 Trial | Calcitonin Gene | Placebo Patient | Adverse Event |
BACKGROUND: Calcitonin gene-related peptide (CGRP) is a validated target for the treatment of episodic migraine. Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine.
METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2b study, we enrolled men and women (aged 18-65 years) from 62 sites in the USA who had migraine headaches 8-14 days per month. ...
| Known for Preventive Treatment | Episodic Migraine | Safety Tolerability | Phase 2b Study | Patients Placebo |
Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial
[ PUBLICATION ]
OBJECTIVE: To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.
METHODS: This was a randomized, placebo-controlled, parallel-group, multicenter study consisting of 16 weeks of double-blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo. An initial dose of ...
| Known for Chronic Migraine | Placebo Treatment | Safety Topiramate | 100 Day | Baseline Monthly |
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial
[ PUBLICATION ]
Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine.
Objective: To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose.
Design and Setting: Randomized, double-blind, placebo-controlled, parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient ...
| Known for Fremanezumab Placebo | Monthly Migraine | Baseline Week | Patients Episodic | Clinical Trial |
OBJECTIVE: Chronic migraine (CM) is a prevalent and disabling neurological disorder. Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program assessed efficacy and safety of onabotulinumtoxinA (BOTOX(®)) for prophylaxis of headaches in adults with CM. This secondary analysis assessed patients who received all five treatment cycles and completed the study.
MATERIALS AND METHODS: PREEMPT (two phase III studies: 24-week double-blind, placebo-controlled [DBPC], ...
| Known for Chronic Migraine | Patients Onabotulinumtoxina | Treatment Cycles | Efficacy Safety | Headache Frequency |
Cluster headache in women: clinical characteristics and comparison with cluster headache in men
[ PUBLICATION ]
OBJECTIVE: To study the clinical characteristics of cluster headache in women. Cluster headache is a disorder of men (male to female ratio 6-7:1).
METHODS: Retrospective chart review to identify all women diagnosed with cluster headache at an academic headache centre from January 1995 through July 1998.
RESULTS: Thirty two women and 69 men were identified. The mean age of onset of cluster headache was 29.4 years in women versus 31.3 years in men. Two peaks of onset in women (2nd and 5th ...
| Known for Cluster Headache | Clinical Characteristics | Onset Women | Female Ratio | Retrospective Chart Review |
OBJECTIVE: To examine the prevalence of migraine in women with chronic pelvic pain with and without endometriosis.
DESIGN: Prospective study of headache, pelvic pain, and quality of life before laparoscopic surgery for pelvic pain. Endometriosis was diagnosed pathologically. Headaches were classified as migraine or non-migraine using International Headache Society criteria.
SETTING: Clinical research hospital.
PATIENT(S): 108 women in a clinical trial for chronic pelvic pain ...
| Known for Pelvic Pain | Women Endometriosis | Prevalence Migraine | Quality Life | Clinical Trial |
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
[ PUBLICATION ]
BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention.
METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North ...
| Known for Amg 334 | Episodic Migraine | 2 Trial | Monoclonal Antibodies | Primary Endpoint |
Stephen David Silberstein: Influence Statistics
| Concept | World rank |
|---|---|
| qd frovatriptan | #1 |
| animals trigeminal sensitization | #1 |
| occurrence menstrual migraine | #1 |
| placebo fremanezumab groups | #1 |
| study medication onset | #1 |
| triptan package size | #1 |
| life 24 hours | #1 |
| migraine headache btxa | #1 |
| efficacy ergotamine | #1 |
| map0004 acute treatment | #1 |
| neuroleptics headache therapy | #1 |
| fremanezumab efficacy outcomes | #1 |
| ades acute treatment | #1 |
| xr topiramate topiramate | #1 |
| repetitive intravenous | #1 |
| hrt menarche | #1 |
| tpm aura migraine | #1 |
| transformed migraine fibromyalgia | #1 |
| migraine sex | #1 |
| aeds migraine prevention | #1 |
| frovatriptan regimens | #1 |
| baseline allodynia time | #1 |
| chronic impact migraine | #1 |
| initial treatment nsaids | #1 |
| attack sensitivity | #1 |
| chronic migraine erenumab | #1 |
| 100 oral sumatriptan | #1 |
| cgrp functionblocking therapy | #1 |
| sinus disease ihs | #1 |
| premenstrual syndrome oestrogen | #1 |
| bothersome question | #1 |
| severe impact lives | #1 |
| hana survey | #1 |
| 50mg tablet | #1 |
| rescue medication bcm | #1 |
| migraineurs xr topiramate | #1 |
| nausea free | #1 |
| frovatriptan eletriptan | #1 |
| acute medication pain | #1 |
| ocs migraine frequency | #1 |
| nasal sinus cases | #1 |
| disorders nausea | #1 |
| bcm study | #1 |
| 33 n6 | #1 |
| headache types studies | #1 |
| 667 patients placebo | #1 |
| menstrual cycle result | #1 |
| rtls general population | #1 |
| 6 adverse events | #1 |
| topiramate benefit | #1 |
Open the FULL List in Excel | |
Key People For Chronic Migraine
Stephen David Silberstein:Expert Impact
Concepts for whichStephen David Silbersteinhas direct influence:Chronic migraine, Cluster headache, Acute treatment, Preventive treatment, Episodic migraine, Menstrual migraine, Migraine prevention, Migraine disorders.
Stephen David Silberstein:KOL impact
Concepts related to the work of other authors for whichfor which Stephen David Silberstein has influence:Chronic migraine, Cluster headache, Botulinum toxin, Acute treatment, Medication overuse.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |